Advanced Filters
noise

amyloidosis Clinical Trials

A listing of amyloidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 161 clinical trials
A Anna Bersano, MD

Enpowering Progression Risk of Cerebral Amyloid Angiopathy

Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical manifestations. Despite recent advances in diagnosis and understanding, many pathogenic, prognostic, and therapeutic aspects remain unclear. Study Objective: PRIORITY is a prospective observational …

18 years of age All Phase N/A
P PI

Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy.

60 years of age All Phase N/A
A Anna Bersano, MD

Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.

The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two cohorts of patients with CADASIL and CAA. A specific aim is to evaluate adherence to the Mediterranean Diet. The …

18 years of age All Phase N/A
J Jennifer Isaacs Clinical Research Services Director

Cardiac Amyloid Biorepository

Use samples procured from patients to improve understanding of molecular, cellular, and tissue-level processes produced by cardiac amyloidosis and therapeutic interventions.

18 years of age All Phase N/A
L Lars Michel, MD

Essen Amyloidosis Registry

The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis. The registry aims to improve the understanding of disease progression, diagnostic pathways, and treatment outcomes. The registry is hosted at the University Hospital Essen and follows patients longitudinally. …

18 years of age All Phase N/A
Y Yan Chang, MD

Beta Amyloid PET/CT in Various Aβ-Related Disease

To evaluate the potential usefulness of 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

18 - 80 years of age All Phase N/A
K Ksenya Tereshchenko

BEAM: Brain-Eye Amyloid Memory Study

The main objectives for this study are: To investigate novel, non-invasive ocular measurements including optical coherence tomography and eye tracking in a cross-sectional study of participants with various neurodegenerative dementias against standard cognitive assessments and brain imaging measures; and To assess the potential utility of ocular assessments for early detection …

50 - 90 years of age All Phase N/A
C Chantal Ms

Florbetaben for Imaging of Vascular Amyloid

The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.

18 years of age All Phase N/A
Y Yen-Hung Lin, MD, PhD

Cardiac Amyloidosis in HFpEF

Heart failure with preserved ejection fraction (HFpEF) accounts for half of heart failure cases with heterogenous cause and variable presentations. The diagnosis of HFpEF required clinical signs and symptoms of HF, normal left ventricular ejection fraction (LVEF) and evidence of diastolic dysfunction. No treatment has been shown in recent major …

60 years of age All Phase N/A
R Robert Perneczky, Prof. Dr.

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's …

50 - 85 years of age All Phase N/A

Simplify language using AI